LONDON, November 27, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
The U.S. equity market edged higher on Tuesday, November 26, 2013. The S&P 500 and the NASDAQ Composite gained 0.01%, 0.58%, respectively, while the Dow Jones Industrial Average finished flat. Shares in the healthcare sector finished on a mixed note, even as the broader market edged higher. The major movers in the sector included Elan Corp PLC (NYSE: ELN), Amarin Corp PLC (NASDAQ: AMRN), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), and Seattle Genetics Inc. (NASDAQ: SGEN). All these companies are tracked by AAAResearchReports.com. Free technical research on ELN, AMRN, CBST, and SGEN can be downloaded upon signing up at:
Elan Corp PLC's stock hit a new 52-week high of $18.17 on Tuesday, before finishing the day flat at $18.13. The company's shares oscillated between $18.04 and $18.17 during the trading session. A total of 4.04 million shares were traded, which is below the daily average volume 6.76 million. The company's shares have surged 12.47% in the last one month and 20.23% in the previous three months, outperforming the S&P 500, which has advanced 2.44% and 8.81% during the respective periods. Furthermore, Elan Corp PLC's stock is trading above its 50-day and 200-day moving averages of $16.48 and $13.94, respectively. Sign up and read the complimentary report on ELN at:
On Tuesday, Amarin Corp PLC's stock surged 2.13%, tracking gains in the broader market. The company's shares fluctuated between $1.87 and $1.95 before closing the day at $1.92. A total of 2.78 million shares were traded, which is below the daily average volume of 8.99 million. The company's shares have lost 3.47% in the previous three trading sessions, underperforming the S&P 500, which has gained 0.38% during the same period. Despite Tuesday's gains, Amarin Corp PLC's stock is trading below its 50-day and 200-day moving averages of $3.82 and $6.06, respectively. The free report on AMRN can be downloaded by signing up now at:
Shares in Cubist Pharmaceuticals Inc. fell by 2.83% on Tuesday, closing the day at $68.76, after fluctuating between $68.35 and $71.09 during the trading session. A total of 0.97 million shares were traded, which is below the daily average volume 1.30 million. Despite Tuesday's decline, the company's shares have advanced 6.92% in the previous three trading sessions and 8.20% in the last one month, compared to a gain of 0.38% and 2.44% in the S&P 500 during the respective periods. Further, Cubist Pharmaceuticals Inc.'s stock is trading above its 50-day and 200-day moving averages of $64.06 and $55.03, respectively. A free report on CBST can be accessed by registering at:
Seattle Genetics Inc.'s stock edged 0.60% lower on Tuesday, closing the day at $41.50 as compared to the previous day's closing price of $41.75. The company's shares oscillated between $41.24 and $42.00 during the trading session. A total of 0.57 million shares were traded, which is below the daily average volume of 0.81 million. Seattle Genetics Inc.'s shares have gained 2.47% in the previous three trading sessions, outperforming the S&P 500, which has gained 0.38% during the same period. Additionally, the company's stock is trading above its 200-moving average of $37.60. Register with AAA Research Reports and download research on SGEN for free at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE AAA Research Reports